Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2007-01-16
2007-01-16
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S229100, C424S204100, C435S006120
Reexamination Certificate
active
10825629
ABSTRACT:
DNA and protein constructs useful in producing vaccines against human cytomegalovirus contain optionally N-end modified and N-terminal ubiquitinated human cytomegalovirus antigenic proteins, including pp65, pp150, IE1, gB and antigenic fragments thereof. Vaccine viruses, in particular poxviruses such as vaccinia and Modified Vaccinia Ankara, that express the constructs may be used as vaccines to augment the immune response to human cytomegalovirus, both prophylatically and in patients already carrying human cytomegalovirus, as well as to create and expand cytomegalovirus-reactive T cells for transfer of adoptive immunity.
REFERENCES:
patent: 5591439 (1997-01-01), Plotkin et al.
patent: 6074645 (2000-06-01), Diamond et al.
patent: 6133433 (2000-10-01), Pande et al.
patent: 6156317 (2000-12-01), Diamond et al.
patent: 6242567 (2001-06-01), Pande et al.
patent: 6251399 (2001-06-01), Diamond et al.
patent: 6440422 (2002-08-01), Sutter et al.
patent: 6544521 (2003-04-01), Diamond
patent: 6562345 (2003-05-01), Diamond et al.
patent: 6632435 (2003-10-01), Diamond
patent: 6632438 (2003-10-01), Paoletti et al.
patent: 6726910 (2004-04-01), Diamond
patent: 6727093 (2004-04-01), Diamond
patent: 6733973 (2004-05-01), Diamond
patent: 6843992 (2005-01-01), Diamond
patent: WO 02/34769 (2002-05-01), None
Adler et al., “A Canarypox Vector Expressing Cytomegalovirus (CMV) Glycoprotein B Primes for Antibody Responses to a Live Attenuated CMV Vaccine (Towne),” J. of Infect. Dis. 180:843-846, 1999.
Aguado et al., “Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3.” Antimicrob. Agents Chemother. 39:1643-1645, 1995.
Allen et al., “Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes From Rhesus Macaques Vaccinated With a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen,” J. Immunol. 164:4968-4978, 2000.
Alp et al., “Fine specificity of cellular immune responses in humans to human cytomegalovirus immediate-early 1 protein.” J. Virol. 65:4812-4820, 1991.
Amara et al., “Different Patterns of Immune Responses but Similar Control of a Simian- Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines.” J. Virol. 76:7625-7631, 2002.
Amara et al., “Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine.” Science 292:69-74, 2001.
Banks et al., “A Major Neutralizing Domain Maps Within the Carboxyl-Terminal Half of the Cleaved Cytomegalovirus B Glycoprotein.” J. Gen. Virol. 70:979-985, 1989.
Basgoz et al., “The Amino Terminus of Human Cytomegalovirus Glycoprotein B Contains Epitopes That Vary Among Strains.” J. of Gen. Virol. 73:983-988, 1992.
Bender et al., “Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza.” J. Virol. 70:6418-6424, 1996.
Berencsi et al., “A Canarypox Vector-Expressing Cytomegalovirus (CMV) Phosphoprotein 65 Induces Long-lasting Cytotoxic T Cell Responses in Human CMV-Seronegative Subjects.” J. Infect. Dis. 183:1171-1179, 2001.
Berencsi et al., “Murine Cytotoxic T Cell Response Specific for Human Cytomegalovirus Glycoprotein B (gB) Induced by Adenovirus and Vaccinia Virus Recombinants Expressing gB.” J. Gen. Virol. 74(pt 11):2507-2512, 1993.
Bernstein et al., “Effect of Previous or Simultaneous Immunization With Canarypox Expressing Cytomegalovirus (CMV) Glycoprotein B (gB) on Response Subunit gB Vaccine Plus MF59 in Healthy CMV-Seronegative Adults.” J. Infect. Dis. 185:686-690, 2002.
Benmohamed et al., “Intranasal Administration of a Synthetic Lipopeptide Without Adjuvant Induces Systemic Immune Responses.” Immunology 106:113-121, 2002.
Blanchard et al., “Modified Vaccinia Virus Ankara Undergoes Limited Replication in Human Cells and Lacks Several Immunomodulatory Proteins: implications for use as a human vaccine.” J. Gen. Virol. 79(Pt 5):1159-1167, 1998.
Boppana et al., “Recognition of Human Cytomegalovirus Gene Products by HCMV-Specific Cytotoxic T Cells.” Virology, 222:293-296, 1996.
Borysiewicz et al., “Human Cytomegalovirus-Specific Cytotoxic T Cells.” J. Exp. Med. 168:919-931, 1988.
Britt et al., “Formulation of an Immunogenic Human Cytomegalovirus Vaccine: Responses in Mice.” J. Infect Dis. 171:18-25, 1995.
Britt et al., “Cell Surface Expression of Human Cytomegalovirus (HCMV) gp55-116 (gB): Use of HCMV-Recombinant Vaccinia Virus-Infected Cells in Analysis of the Human Neutralizing Antibody Response.” J. Virol. 64:1079-1085, 1990.
Carroll et al., “Host Range and Cytopathogenicity of the Highly Attenuated MVA Strain of Vaccinia Virus: Propagation and Generation of Recombinant Viruses in a Nonhuman Mammalian Cell Line.” Virology 238:198-211, 1997.
Carroll et al., “Highly Attenuated Modified Vaccinia Virus Ankara (MVA) As An Effective Recombinant Vector: A Murine Tumor Model.” Vaccine 15 (4):387-394, 1997.
Chee et al., “Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD169.” Current Topics in Microbiol. Immunol. 154:126-169, 1990.
Cranage et al., “Identification of the Human Cytomegalovirus Glycoprotein B Gene and Induction of Neutralizing Antibodies Via Its Expression in Recombinant Vaccinia Virus.” EMBO J. 5(11):3057-3063, 1986.
D'Amaro et al., “A Computer Program for Predicting Possible Cytotoxic T Lymphocyte Epitopes Based on HLA Class I Peptide-Binding Motifs.” Human Immunol. 43:13-18, 1995.
Degano et al., “Gene Gun Intradermal DNA Immunization Followed By Boosting With Modified Vaccinia Virus Ankara: Enhanced CD8* T Cell Immunogenicity and Protective Efficacy in the Influenza and Malaria Models.” Vaccine 18:623-632, 2000.
Delogu et al., “DNA Vaccine Combinations Expressing Either Tissue Plasminogen Activator Signal Sequence Fusion Proteins or Ubiquitin-Conjugated antigens Induce Sustained Protective Immunity in a Mouse Model of pulmonary Tuberculosis.” Infect. and Immunity 70:292-302, 2002.
Delogu et al., “DNA Vaccination against Tuberculosis: expression of a ubiquitin- conjugated tuberculosis protein enhances antimycobacterial immunity.” Infect. Immunity 68.6:3097-3102, 2000.
Diamond et al., “Development of a Candidate HLA A*0201 Restricted Peptide-Based Vaccine Against Human Cytomegalovirus Infection.” Blood 90(5):1751-1767, 1997.
Einsele et al., “Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide.” Cytotherapy 4:49-54, 2002.
Elkington et al., “Ex Vivo Profiling of CD8*-T-Cell Responses to Human Cytomegalovirus Reveals Broad and Multispecific Reactivities in Healthy Virus Carriers.” J. Virol. 77(9):5226-5240, 2003.
Endresz et al., “Induction of Human Cytomegalovirus (HCMV)-Glycoprotein B (gB)-Specific Neutralizing Antibody and Phosphoprotein 65 (pp65)-Specific Cytotoxic T Lymphocyte Responses By Naked DNA Immunization.” Vaccine 17:50-58, 1999.
Endresz et al., “Optimization of DNA Immunization Against Human Cytomegalovirus.” Vaccine 19:3972-3980, 2001.
Firat et al., “Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/ HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice.” Int. Immunol. 14:925-934, 2002.
Fu et al., “Induction of MHC Class I-Restricted CTL Responses by DNA Immunization with Ubiquitin-Influenza Virus Nucleoprotein Fusion Antigens.” Vaccine 16(18):1711-1717, 1998.
Gallez-Hawkins et al., “Kinase-Deficient CMVpp65 Triggers a CMVpp65 Specific T-Cell Immune Response in HLA-A*0201.Kb Transgenic Mice after DNA Immunization.” Scand. J. Immunol. 5
Diamond Don Jeffrey
Wang Zhongde
City of Hope
Rothwell, Figg, Ernst & Manbeck pc
Salimi Ali R.
LandOfFree
Human cytomegalovirus antigens expressed in MVA and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human cytomegalovirus antigens expressed in MVA and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human cytomegalovirus antigens expressed in MVA and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3731273